On March 16, 2024, hundreds of #insulin4all advocates participated in over a dozen events across the globe calling for insulin access and affordability as part of the Global Day of Action for #insulin4all, sharing their stories on the critical need for insulin equity now. Read more
As a person living with type 1 diabetes who has been involved with T1International since 2019, I’m so proud to step into the role of Board Chair of Trustees this year. I believe in this organisation and this cause deeply because it is personal to me. I live with the ups and downs of diabetes, and I believe in health justice for everyone who is faced with this condition worldwide. Read more
As we begin 2024 and think about the plans for T1International this year and beyond, I wanted to share a personal update that is also a big organisational update. After over a decade of leading T1International, the time has come for me to transition from my role as Executive Director by the end of 2024. This decision was not made lightly. Read more
The #insulin4all movement has had some major victories lately. For example, Medicare beneficiaries can access $35 copays for some insulins. The list price of insulin went down for nine insulins. Over half of the states in the USA have passed some form of insulin copay cap. These victories were hard fought by #insulin4all advocates over the past decade. But we’re not celebrating the much heralded $35 insulin cap for all. Because it’s not true.
Read more
Only eight days of National Diabetes Awareness Month had passed this November when pharmaceutical company Novo Nordisk announced it would be pulling Levemir, a long-acting insulin that millions of insulin-dependent diabetic patients depend on, from the U.S. market. Read more
To kick off Diabetes Awareness Month, the Global Diabetes compact held a two-day meeting where T1International and 35 other organisations in over 25 countries presented the goal of the Fight for Five campaign. We showed the depth and breadth of support for this campaign not only through stories of patients most impacted by lack of affordable and accessible insulin in their home countries, but also by the number of organisations that support a better world for people with diabetes. Read more
We are pleased to announce that the 2023 WHO EML, released yesterday, now includes disposable and reusable pens with cartridges for human insulin. You may remember that two years ago, T1International’s advocacy was instrumental in the WHO’s decision to add long-acting insulin analogues in vials and pens to its EML. This week’s decision paves the way for short-acting insulin analogues to be added to the WHO EML in 2025 in both vial and pen preparations. Read more
On March 1, Eli Lilly announced it would reduce the list prices of some of its insulins, including the generic Lispro, the same product as the name-brand Humalog. At a recent congressional hearing with the CEOs of insulin manufacturers and pharmacy benefit managers, David Ricks, Eli Lilly’s CEO, again celebrated that $25 insulin lispro was available to patients as of May 1. People with diabetes have worked tirelessly to reduce insulin costs for decades. So why aren’t we universally celebrating this announcement of lower prices? Because it is now the end of May, and I - and many others in my community - still haven’t been able to get the promised $25 insulin.
Read more
Advocates recently gathered in Washington, DC to attend the Senate HELP Committee Hearing entitled: The Need to Make Insulin Affordable for All Americans. The hearing, led by Chairman Senator Bernie Sanders, is the culmination of a decade of advocacy efforts by the #insulin4all community who have demanded public accountability for the global insulin price crisis. Read more
Following years of advocacy on affordable insulin for T1International, today Eli Lilly announced that vials of generic insulin Lispro will be available to all US customers for $25 effective May 1, 2023. Some other Eli Lilly insulins will also be made more affordable by the end of the year. Current list prices for insulin can be over $300 per vial. Read more